Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$9 Mln
P/E Ratio
--
P/B Ratio
0.11
Industry P/E
--
Debt to Equity
0
ROE
-4.9 %
ROCE
--
Div. Yield
0 %
Book Value
-1.96
EPS
--
CFO
$-40.40 Mln
EBITDA
$-43.38 Mln
Net Profit
$-64.12 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Transcode Therapeutics Inc (RNAZ)
| -88.72 | -45.14 | -94.60 | -97.38 | -98.25 | -- | -- |
|
BSE Sensex*
| 2.32 | 3.16 | 6.23 | 8.59 | 12.11 | 20.32 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Transcode Therapeutics Inc (RNAZ)
| -98.40 | -98.77 | -73.50 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a... master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts. Read more
Interim CEO, CFO, President, VP of Administration & Director
Mr. Thomas A. Fitzgerald M.B.A.
Interim CEO, CFO, President, VP of Administration & Director
Mr. Thomas A. Fitzgerald M.B.A.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Transcode Therapeutics Inc (RNAZ) stood at $ 14 Mln as on 31-Mar-25
The share price of Transcode Therapeutics Inc (RNAZ) is $0.38 (NASDAQ) as of 25-Apr-2025 16:27 EDT. Transcode Therapeutics Inc (RNAZ) has given a return of -98.25% in the last 3 years.
Transcode Therapeutics Inc (RNAZ) has a market capitalisation of $ 9 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Transcode Therapeutics Inc (RNAZ) is 0.11 times as on 25-Apr-2025, a 95% discount to its peers’ median range of 2.29 times.
Since, TTM earnings of Transcode Therapeutics Inc (RNAZ) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Transcode Therapeutics Inc (RNAZ) and enter the required number of quantities and click on buy to purchase the shares of Transcode Therapeutics Inc (RNAZ).
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
The CEO & director of Mr. Thomas A. Fitzgerald M.B.A.. is Transcode Therapeutics Inc (RNAZ), and CFO & Sr. VP is Mr. Thomas A. Fitzgerald M.B.A..
There is no promoter pledging in Transcode Therapeutics Inc (RNAZ).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Transcode Therapeutics Inc (RNAZ) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Transcode Therapeutics Inc (RNAZ) was $0 Mln.
$-0.02
(
